SLC5A2 and heart failure: Recently, SGLT2 inhibitors, especially empagliflozin, have also been shown to improve diastolic dysfunction and heart failure outcomes in both rodent models and humans with HFpEF through a reduction in wall stress by decreasing preload and altered hemodynamics [34].